- Home
- SNPX vs APM Comparison
SNPX vs APM Comparison
Compare SNPX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- APM
- Stock Information
- Founded
- SNPX 2012
- APM 2010
- Country
- SNPX United States
- APM United Kingdom
- Employees
- SNPX N/A
- APM N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SNPX Health Care
- APM Health Care
- Exchange
- SNPX Nasdaq
- APM Nasdaq
- Market Cap
- SNPX 3.7M
- APM 4.1M
- IPO Year
- SNPX N/A
- APM 2018
- Fundamental
- Price
- SNPX $3.30
- APM $1.15
- Analyst Decision
- SNPX Strong Buy
- APM
- Analyst Count
- SNPX 1
- APM 0
- Target Price
- SNPX $14.00
- APM N/A
- AVG Volume (30 Days)
- SNPX 33.7K
- APM 7.0M
- Earning Date
- SNPX 11-12-2024
- APM 12-20-2024
- Dividend Yield
- SNPX N/A
- APM N/A
- EPS Growth
- SNPX N/A
- APM N/A
- EPS
- SNPX N/A
- APM 0.00
- Revenue
- SNPX N/A
- APM N/A
- Revenue This Year
- SNPX N/A
- APM $157,729.10
- Revenue Next Year
- SNPX N/A
- APM N/A
- P/E Ratio
- SNPX N/A
- APM $345.64
- Revenue Growth
- SNPX N/A
- APM N/A
- 52 Week Low
- SNPX $2.32
- APM $0.46
- 52 Week High
- SNPX $7.23
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- SNPX 51.02
- APM 47.12
- Support Level
- SNPX $3.10
- APM $1.21
- Resistance Level
- SNPX $3.58
- APM $1.30
- Average True Range (ATR)
- SNPX 0.33
- APM 0.75
- MACD
- SNPX -0.03
- APM -0.06
- Stochastic Oscillator
- SNPX 32.04
- APM 4.58
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.